On Tuesday, the World Health Organization (WHO) stated that it will undertake a decision on giving the emergency use listing (EUL) to Bharat Biotech’s COVID-19 vaccine, Covaxin by next week, stated reports.
The global health body took to Twitter to elaborate on how WHO along with an independent group of experts are slated to meet next week to undertake risk, benefit examination and arrive at a final decision on whether to grant EUL to Covaxin. This update comes to post the Hyderabad based firm making a presentation on the efficacy and safety data of its vaccine to the expert body that advises the WHO, the strategic advisory group of experts on immunization (SAGE).
WHO & an independent group of experts are scheduled to meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant Emergency Use Listing to Covaxin.#COVID19pic.twitter.com/jJyS1hiz44
— World Health Organization (WHO) (@WHO) October 5, 2021
According to the global health body, Bharat Biotech on a rolling basis has been presenting data to it and has even given further details upon its request on September 27.
It elaborated that the experts from WHO are presently examining this information and if it answers all the questions posed, an assessment from the WHO will be made next week. On Tuesday, a meeting was held, wherein the company made a presentation of the clinical data from the phase 1,2,3 of Covaxin and after-marketing tests on immunogenicity, safety, effectiveness and efficacy to the SAGE.
Also Read: BMC Aims To Vaccinate 35 Lakh Citizens In October
Share
Tweet
